{"id":"testosterone-undecanoate-alone","safety":{"commonSideEffects":[{"rate":null,"effect":"Polycythemia"},{"rate":null,"effect":"Acne"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Prostate-related effects"}]},"_chembl":{"chemblId":"CHEMBL2107067","moleculeType":"Small molecule","molecularWeight":"456.71"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Testosterone undecanoate is a long-acting ester of testosterone that, when administered, is hydrolyzed to release free testosterone. It binds to androgen receptors throughout the body to restore physiological testosterone levels and promote androgenic and anabolic effects. This mechanism is used to treat testosterone deficiency states and potentially other conditions where androgen supplementation is therapeutically beneficial.","oneSentence":"Testosterone undecanoate is an androgen that binds to androgen receptors to replace or supplement testosterone in the body.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:13.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Testosterone deficiency (hypogonadism)"},{"name":"Male infertility (potential indication in phase 3)"}]},"trialDetails":[{"nctId":"NCT07187947","phase":"","title":"Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-07-18","conditions":"Gender Incongruence, Cardiovascular (CV) Risk, Cardiovascular Disease Risk Factor","enrollment":500},{"nctId":"NCT06188767","phase":"NA","title":"Testosterone-induced Muscle Memory and Underlying Mechanisms","status":"RECRUITING","sponsor":"Morten Hostrup, PhD","startDate":"2025-04-01","conditions":"Skeletal Muscle Physiology","enrollment":30},{"nctId":"NCT05435222","phase":"NA","title":"Evaluation of a Male-specific Psychotherapeutic Program for Major Depressive Disorders","status":"RECRUITING","sponsor":"Andreas Walther","startDate":"2023-03-15","conditions":"Major Depressive Disorder","enrollment":244},{"nctId":"NCT06393634","phase":"EARLY_PHASE1","title":"Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration","status":"COMPLETED","sponsor":"Sports Medicine Research and Testing Laboratory","startDate":"2024-11-27","conditions":"Healthy","enrollment":14},{"nctId":"NCT06312761","phase":"PHASE1, PHASE2","title":"Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2024-06-01","conditions":"Hypogonadism, Male","enrollment":10},{"nctId":"NCT04120363","phase":"PHASE4","title":"Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2019-09-23","conditions":"Caloric Restriction, Exercise, Sleep","enrollment":34},{"nctId":"NCT00924612","phase":"PHASE2","title":"Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2009-07","conditions":"Male Hypogonadism","enrollment":16},{"nctId":"NCT02966652","phase":"PHASE1","title":"Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2016-11-03","conditions":"Male Hypogonadism","enrollment":25},{"nctId":"NCT03379012","phase":"PHASE2","title":"Testosterone in Metastatic Renal Cell Carcinoma Patients","status":"COMPLETED","sponsor":"Kidney Cancer Research Bureau","startDate":"2016-02-08","conditions":"Metastatic Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT03335254","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males","status":"TERMINATED","sponsor":"TesoRx Pharma, LLC","startDate":"2017-11-06","conditions":"Hypogonadism, Hypogonadism, Male, Gonadal Disorders","enrollment":9},{"nctId":"NCT02697188","phase":"PHASE2","title":"Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2007-11","conditions":"Hypogonadism","enrollment":12},{"nctId":"NCT00146146","phase":"PHASE3","title":"Testosterone and Its Metabolites in GID","status":"COMPLETED","sponsor":"Unita Complessa di Ostetricia e Ginecologia","startDate":"2005-05","conditions":"Transsexualism","enrollment":15},{"nctId":"NCT02670343","phase":"PHASE1, PHASE2","title":"Phlebotomy Study of Testosterone Undecanoate","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2016-01","conditions":"Hypogonadism","enrollment":8},{"nctId":"NCT02722278","phase":"PHASE3","title":"A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2016-03","conditions":"Hypogonadism","enrollment":222},{"nctId":"NCT01919294","phase":"PHASE2","title":"Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS)","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2013-07","conditions":"Nonalcoholic Steatohepatitis, Hypogonadism","enrollment":3},{"nctId":"NCT02222558","phase":"PHASE2","title":"Oral Testosterone for the Treatment of Hypogonadism in Males","status":"COMPLETED","sponsor":"TesoRx Pharma, LLC","startDate":"2014-09","conditions":"Hypogonadism","enrollment":25},{"nctId":"NCT01717768","phase":"PHASE2","title":"Oral Testosterone for the Treatment of Hypogonadism","status":"COMPLETED","sponsor":"TesoRx Pharma, LLC","startDate":"2012-10","conditions":"Hypogonadism","enrollment":130},{"nctId":"NCT01092858","phase":"PHASE4","title":"NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)","status":"TERMINATED","sponsor":"Bayer","startDate":"2010-09","conditions":"Hypogonadism","enrollment":4},{"nctId":"NCT00117000","phase":"PHASE3","title":"The Effects of Testosterone and Nutritional Supplementation in the Undernourished Elderly","status":"UNKNOWN","sponsor":"University of Adelaide","startDate":"2003-07","conditions":"Malnutrition, Aging","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":63,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nebid"],"phase":"phase_3","status":"active","brandName":"testosterone undecanoate alone","genericName":"testosterone undecanoate alone","companyName":"Unita Complessa di Ostetricia e Ginecologia","companyId":"unita-complessa-di-ostetricia-e-ginecologia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Testosterone undecanoate is an androgen that binds to androgen receptors to replace or supplement testosterone in the body. Used for Testosterone deficiency (hypogonadism), Male infertility (potential indication in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}